Rochester, NY 9/1/2009 11:54:38 AM
Schering-Plough Corporation SGP,Up 0.57% stronger after the market trade
Schering-Plough Corporation
Schering-Plough has settled a patent lawsuit against Orchid Chemicals & Pharmaceuticals and Orgenus Pharma over their proposed generic versions of solid oral dosage formulations of the allergy drug Clarinex. The agreement will allow Chennai, India-based Orchid, which had alleged that the ’274 and ’223 patents covering the drug are invalid, to introduce a generic version of Clarinex (desloratadine) orally disintegrating tablets Jan. 1, 2012, and Clarinex 5-mg tablets July 1, 2012, Schering-Plough says in a statement. Orgenus is a U.S. subsidiary of Orchid.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 28.18
Day's Range: 27.81 - 28.32
52wk Range: 11.97 - 28.67
Change: Up 0.16 (0.57%)
Volume: 6,987,585
Avg Vol (3m): 13,945,600
About Schering-Plough Corporation
Schering-Plough Corporation (Schering-Plough) is a global science-centered healthcare company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough discovers, develops and manufactures pharmaceuticals for prescription, animal health, and consumer markets. The Company operates in three segments: Prescription Pharmaceuticals, Animal Health and Consumer Health Care. The Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. The Animal Health segment discovers, develops, manufactures and markets animal health products. The Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, primarily in the United States.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
